The ACUTE (Ambulance CPAP: Use, Treatment effect and economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure by Fuller, G.W. et al.
This is a repository copy of The ACUTE (Ambulance CPAP: Use, Treatment effect and 
economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for 
acute respiratory failure.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/132177/
Version: Published Version
Article:
Fuller, G.W. orcid.org/0000-0001-8532-3500, Goodacre, S., Keating, S. et al. (11 more 
authors) (2018) The ACUTE (Ambulance CPAP: Use, Treatment effect and economics) 
feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute 
respiratory failure. Pilot and Feasibility Studies, 4 (1). 86. ISSN 2055-5784 
https://doi.org/10.1186/s40814-018-0281-9
© The Author(s). 2018. This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which 
permits unrestricted use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a link to the Creative 
Commons license, and indicate if changes were made. The Creative Commons Public 
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to 
the data made available in this article, unless otherwise stated.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
STUDY PROTOCOL Open Access
The ACUTE (Ambulance CPAP: Use,
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study: a pilot randomised controlled trial of
prehospital CPAP for acute respiratory
failure
Gordon W. Fuller1*, Steve Goodacre1, Samuel Keating2, Gavin Perkins3, Matthew Ward4, Andy Rosser4,
Imogen Gunson4, Joshua Miller4, Mike Bradburn2, Praveen Thokala5, Tim Harris6, Andrew Carson4,
Maggie Marsh7 and Cindy Cooper2
Abstract
Background: Acute respiratory failure (ARF) is a common and life-threatening medical emergency. Standard prehospital
management involves controlled oxygen therapy and disease-specific ancillary treatments. Continuous positive airway
pressure (CPAP) is a potentially beneficial alternative treatment that could be delivered by emergency medical services.
However, it is uncertain whether this treatment could work effectively in United Kingdom National Health Service (NHS)
ambulance services and if it represents value for money.
Methods: An individual patient randomised controlled external pilot trial will be conducted comparing prehospital CPAP
to standard oxygen therapy for ARF. Adults presenting to ambulance service clinicians will be eligible if they have
respiratory distress with peripheral oxygen saturation below British Thoracic Society (BTS) target levels, despite titrated
supplemental oxygen. Enrolled patients will be allocated (1:1 simple randomisation) to prehospital CPAP (O_two system)
or standard oxygen therapy using identical sealed boxes. Feasibility outcomes will include incidence of recruited eligible
patients, number of erroneously recruited patients and proportion of cases adhering to allocation schedule and
treatment, followed up at 30 days and with complete data collection. Effectiveness outcomes will comprise survival at
30 days (definitive trial primary end point), endotracheal intubation, admission to critical care, length of hospital stay,
visual analogue scale (VAS) dyspnoea score, EQ-5D-5L and health care resource use at 30 days. The cost-effectiveness
of CPAP, and of conducting a definitive trial, will be evaluated by updating an existing economic model. The trial aims
to recruit 120 patients over 12 months from four regional ambulance hubs within the West Midlands Ambulance
Service (WMAS). This sample size will allow estimation of feasibility outcomes with a precision of < 5%. Feasibility and
effectiveness outcomes will be reported descriptively for the whole trial population, and each trial arm, together with
their 95% confidence intervals.
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Discussion: This study will determine if it is feasible, acceptable and cost-effective to undertake a full-scale trial
comparing CPAP and standard oxygen treatment, delivered by ambulance service clinicians for ARF. This will inform
NHS practice and prevent inappropriate prehospital CPAP adoption on the basis of limited evidence and at a
potentially substantial cost.
Trial registration: ISRCTN12048261. Registered on 30 August 2017. http://www.isrctn.com/ISRCTN12048261
Keywords: Acute respiratory failure, Continuous positive airways pressure, Prehospital, Emergency medical services
Background
Acute respiratory failure (ARF) is a common medical
emergency which occurs when disease of the heart or
lungs lead to failure to maintain adequate blood oxygen
levels and/or increased blood carbon dioxide levels [1]. It
is caused by a number of common cardiac or respiratory
diseases, including heart failure, pneumonia, and exacer-
bations of chronic obstructive pulmonary disease (COPD)
and asthma [2]. There are approximately 3000 ARF cases
in England per year, with a high 14% risk of death within
30 days [3]. ARF has substantial health services costs, with
patients often requiring prolonged hospital stays, ventila-
tory support and critical care admissions [4]. ARF was re-
sponsible for over 3 million National Health Service
(NHS) bed days in England in 2014 [5].
Current prehospital clinical practice guidelines recom-
mend a standard management approach of oxygen ther-
apy for the treatment of acute respiratory failure,
supplemented by specific management options directed
at the underlying disease [6–8]. Prehospital administra-
tion of continuous positive airway pressure (CPAP) may
be a potentially beneficial alternative treatment strategy
[9]. CPAP involves delivering oxygen-enriched air to the
lungs at increased pressure through a close-fitting face
mask and is widely used in hospital to treat ARF from a
number of causes [10]. It has been suggested that CPAP
may be more effective if delivered earlier, i.e. en route to
hospital [11]. The difficulties of prehospital diagnosis
mean that prehospital CPAP is likely to be applied gen-
erally to all cases of acute respiratory failure, rather than
directed towards those due to a specific cause [12].
A recent evidence synthesis reported that prehospital
CPAP reduced the risk of mortality and requirement for
endotracheal intubation in ARF compared to standard
treatment but noted that the primary studies were rela-
tively small, heterogeneous, at risk of bias and may not
be applicable to the NHS [3, 9]. A recent economic
evaluation suggested that prehospital CPAP was more
effective than standard care but was also more expen-
sive, with an incremental cost-effectiveness ratio of
£20,514/quality-adjusted life year (QALY) and a 49.5%
probability of being cost-effective at the £20,000/QALY
threshold. Expected value of perfect information (EVPI)
analyses suggested that further research costing up to
£22.5 million could represent value for money, while ex-
pected value of sample information (EVSI) analyses sug-
gested that a randomised trial recruiting 1000 patients
per arm would be cost-effective if research costs were
less than £18.1 million. However, these cost-effectiveness
results were predicated on the accuracy of published ef-
fectiveness data and were very sensitive to estimates for
the incidence of acute respiratory failure.
Taken together, these findings suggest that although
prehospital CPAP is a promising therapy, further re-
search is needed to examine whether the reported clin-
ical and cost-effectiveness are confirmed in the UK
setting. Prior to a large pragmatic trial and economic
evaluation comparing prehospital CPAP to standard
care, it is first necessary to estimate the incidence of eli-
gible patients and to assess whether a trial would be
feasible and cost-effective. We also need to determine
whether prehospital CPAP can be delivered in the con-
text of the NHS ambulance service. Prehospital trials
need to overcome a number of potential practical bar-
riers if they are to deliver valid data. For these reasons, a
stand-alone feasibility study is necessary to estimate the
incidence of eligible patients and test the feasibility and
acceptability of potential definitive trial methods.
Methods
Study design, aims and objectives
The ACUTE study is a stand-alone, randomised, parallel
group, external pilot trial. A concurrent health economic
evaluation will also be performed, updating an existing
decision analytic model [3]. The study aims to determine
the feasibility, acceptability and cost-effectiveness of a
definitive trial to evaluate the clinical and cost-
effectiveness of prehospital CPAP compared to standard
oxygen therapy, for patients attended by ambulance ser-
vice clinicians with ARF. The study design is sum-
marised in Fig. 1 and the schedule of enrolment,
interventions and assessments summarised in Table 1.
The primary objectives are to estimate the following
feasibility outcomes:
1. The rate of eligible patients per 100,000 population
per year
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2. The proportion recruited and allocated to treatment
appropriately
3. Adherence to allocated treatment
4. Retention and data completeness up to 30 days
5. Expected net benefit of sampling for a range of study
sizes to identify the optimal definitive trial design
Secondary objectives are to estimate the following
summary clinical outcome measures, across the whole
trial population and per treatment group:
1. Proportion surviving to 30 days
2. Proportion undergoing endotracheal intubation by
30 days
3. Proportion admitted to critical care at any point up
to 30 days
4. Mean and median length of hospital stay
5. Change in visual analogue scale (VAS) dyspnoea score
from presentation to immediately before ED arrival
6. Mean change in quality of life, measured with EQ-
5D-5L
7. Key elements of health care resource use up to
30 days
This clinical data will be used to update an existing net-
work meta-analysis and economic model, [3, 9] to deter-
mine the cost-effectiveness of prehospital CPAP given
current evidence. The summary clinical outcome measures
will also inform the design of any future definitive trial.
Setting and study population
The study will take place in the West Midlands Ambulance
Service (WMAS), which serves a mixed urban and rural
population of 5.6 million. It employs approximately 4000
Fig. 1 Flowchart of participants through the ACUTE study [CONSORT diagram]
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staff across five divisions and operates from 15 ‘super-hubs’,
each covering five to ten community ambulance stations.
Recruitment will take place across four super-hubs in two
divisions covering a population of 1.5 million. Included
hubs were chosen to provide a representative mixture of
urban, semi-urban and rural localities.
The study population will comprise adults transported
to hospital by emergency ambulance with ARF. Inclu-
sion and exclusion criteria will be based on ambulance
service clinician judgement at the scene of incident.
Acute respiratory failure will be defined as respiratory
distress with peripheral oxygen saturation below British
Thoracic Society (BTS) target levels (88% for patients
with COPD, 94% for other conditions), despite supple-
mental oxygen (titrated low flow oxygen for COPD, or
titrated high flow oxygen in other conditions) [13].
Potential participants will be excluded if any of the fol-
lowing criteria are met:
1. Hospital CPAP treatment available within 15 min of
eligibility assessment
2. Age < 18 years
3. Known to have terminal illness
4. Known pre-existing lack of capacity (confirmed
by relatives, carers or documentary evidence,
such as lasting power of attorney)
5. Documented not for resuscitation status
6. Acutely incapacitated patients with known
valid advanced directive declining non-invasive
ventilation or participation in research
7. The patient has an oxygen alert card
8. Anticipated inability to apply CPAP
(e.g. facial deformity)
9. Respiratory failure due to chest trauma
10. Contraindication to CPAP (suspected
pneumothorax, respiratory arrest, epistaxis,
vomiting, hypotension)
11. Previous enrolment in the ACUTE trial
12. Pregnancy
13. Patients unable to communicate with ambulance
service clinicians
Randomisation, allocation concealment and participant
enrolment
Patients presenting to ambulance service clinicians with
ARF will be individually randomised to CPAP or stand-
ard oxygen therapy in a 1:1 ratio using simple, unre-
stricted randomisation. The randomisation sequence will
be computer-generated by an independent statistician
who is not directly involved in the conduct of the trial.
The allocation sequence will be held centrally on a
password-protected, access-restricted network drive.
The trial statistician will not have access to the random-
isation sequence until after data lock. Due to the phys-
ical differences between the CPAP device and standard
oxygen mask, it is not possible to blind patients, ambu-
lance service clinicians or hospital clinicians to the treat-
ment arms. Outcome assessors will also not be blinded.
However, both primary and secondary endpoints com-
prise ‘hard’ objective measurements, minimising the
possibility of information bias.
CPAP devices (intervention arm) and high-concentration
oxygen therapy masks (control arm) will be packaged in
identical equipment boxes measuring approximately
170 mm× 170 mm× 70 mm. The boxes will be tamper-
proof and equal in weight and appearance to maintain
Table 1 Schedule of enrolment, interventions and assessments
Study period
Enrolment Allocation Post-allocation
Time point 0–5 min 5–10 min 10–60 min 1–5 h 1–29 days 30 days 30–37 days
Enrolment
Eligibility screen X
Informed consent X X
Allocation X
Interventions
CPAP X
Standard oxygen therapy X
Assessments
Patient characteristics X X X
ED physiology and treatments X
Hospital treatments X
Clinical outcomes X
Quality of life and health resource use X
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allocation concealment. Boxes can only be opened after a
patient is definitively enrolled in the trial. Once a box is
opened when attending a patient, that patient will be in-
cluded in the study as per allocated treatment. It will not be
possible to re-seal the box. Equipment boxes will be assem-
bled, numbered and sealed in accordance with the alloca-
tion sequence by researchers not directly involved in the
conduct of the trial, under the supervision of the trial man-
ager. Boxes will then be transferred to the central WMAS
storage and distribution centre where they will be held in
an access-restricted research store. Boxes will subsequently
be supplied to participating ambulance hubs as required by
the WMAS internal distribution team and held locally in a
designated storage area. Ambulance service clinicians will
then collect an equipment box at the beginning of each
shift. At the end of the shift, boxes will be returned to the
ambulance hub equipment store. Boxes will be signed in
and out for each shift with ambulance service clinician, am-
bulance and equipment box details recorded in a distribu-
tion log. Research paramedics will monitor the condition,
status and location of boxes on a weekly basis to ensure
concealment of the allocation sequence until treatment as-
signment occurs.
Ambulance service clinicians (paramedics, ambulance
technicians, paramedic practitioners or critical care
paramedics) will identify patients with ARF when at-
tending 999 ambulance calls. Patients meeting trial in-
clusion criteria will be approached for enrolment in the
trial guided by a standardised script. If possible, verbal
consent will be obtained for participation prior to enrol-
ment. Patients lacking capacity will be enrolled accord-
ing to a hierarchical consent process complying with the
Mental Capacity Act (MCA) 2005 [14] described below.
Immediately after inclusion, ambulance service clinicians
will open the trial equipment box and provide treatment
according to whether a CPAP device or high-
concentration oxygen mask is supplied.
Consent
A hierarchical consent process will be used complying
with the Mental Capacity Act (MCA) 2005 [14]. Verbal
consent will be obtained for enrolment if the treating
ambulance service clinician determines that the patient
has capacity. Ambulance service clinicians will enrol pa-
tients without consent if the patient does not have cap-
acity. In either case, a research paramedic will review the
participant in hospital as soon as possible after enrol-
ment, provide verbal and written information regarding
the study and seek written informed consent as soon as
the participant has capacity. If the patient does not re-
gain capacity, we will seek advice from a personal con-
sultee for enrolment in the trial [15]. When a personal
consultee is unavailable, a nominated consultee will be
approached for a consent waiver [15]. If patients (or
their consultees) decline consent, all non-identifiable
data up to the point of refusal will be retained. No fur-
ther data collection will be conducted from this point
onwards, except for anonymised 30-day mortality data.
Trial treatments
Patients in the intervention arm will be treated by CPAP
with supplemental oxygen. Patients in the control arm
will receive standard oxygen therapy. Treatment in both
arms will be targeted to BTS guidelines for peripheral
oxygen saturations [13]. Ancillary condition-specific
treatments will be administered in both trial arms ac-
cording to standard practice guidelines [8]. Ambulance
service clinicians (paramedics, ambulance technicians,
paramedic practitioners or critical care paramedics) will
deliver trial treatments.
Intervention arm
CPAP is a form of non-invasive ventilation (NIV) where
oxygen or air is supplied to the upper airways at in-
creased pressure [16]. The ACUTE trial will use the O_
two unit, a lightweight, open, single-use, low-flow CPAP
system [17]. The device consists of tubing, which is con-
nected to an oxygen source (either a portable oxygen cy-
linder or the usual ambulance oxygen flow regulator),
and an in-line CPAP unit connecting to a close-fitting
face mask. The CPAP unit entrains ambient air to in-
crease local mask pressure, providing resistance for the
patient to breathe against. The level of CPAP is varied
by altering the incoming oxygen flow rate. Thus, the in-
spired concentration of oxygen varies according to the
desired degree of CPAP, as the flow rate is altered. As an
open system, with access to ambient air, the device al-
lows unrestricted inspiratory flows and is unaffected by
respiratory rate.
Treatment may be commenced at the site of initial
clinical contact or after transfer to an ambulance. An ap-
propriately sized mask will be used, with CPAP started
at 5 cm H2O and then incrementally increased by 1 cm
H2O every 2–5 min to a maximum of 15 cm H2O ac-
cording to BTS peripheral oxygen saturation targets [13]
measured by standard pulse oximetry. Target peripheral
oxygen saturations will be 88–92% for patients with
known/suspected COPD and 94–98% for patients with
other suspected causes of acute respiratory failure. If ne-
cessary, nebuliser treatments can be positioned between
the face mask and the O_two CPAP unit. CPAP will be
continued until arrival at hospital unless not tolerated (e.
g. patient request, claustrophobia, anxiety, significant
agitation); patient is unable to maintain own airway; de-
crease in systolic blood pressure to < 90 mmHg; vomit-
ing; epistaxis; conscious level decreases and patient does
not respond to voice; patient improvement; or suspected
pneumothorax.
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Control arm
Oxygen will be delivered at normal atmospheric pressure
from a compressed gas tank (or portable oxygen cylinder),
via a flow regulator, to the patient using nasal cannula, an
air entrainment ‘Venturi’ mask, a simple face mask or a
non-rebreathing reservoir face mask. The exact choice of
flow rate and oxygen delivery device will be determined by
ambulance service clinicians according to the patient’s
condition and peripheral oxygen saturation levels. Target
oxygen saturations will be 88–92% for patients with
known or suspected COPD and 94–98% for other sus-
pected causes of acute respiratory failure.
On arrival at hospital emergency department, staff will
be informed of the study and current treatment. Patient
care will then be transferred from ambulance service cli-
nicians to hospital clinicians according to normal prac-
tice. Care will subsequently continue according to
hospital guidelines as implemented by the hospital clin-
ician. In the intervention group, the hospital clinician
will determine whether to continue NIV using the O_
two unit, switch to an in-hospital system or discontinue
NIV altogether. Patients in the control group will be able
to receive in-hospital NIV if indicated, according to as-
sessment by the hospital clinician.
The West Midlands Ambulance Service (WMAS), O_
two representatives and research paramedics will provide
training and support for all ambulance service clinicians
based at the participating ambulance hubs. This will in-
volve training in identification of eligible patients, applica-
tion of the inclusion/exclusion criteria, providing
appropriate information and seeking consent, randomisa-
tion, delivery of CPAP, monitoring for adverse events
(AEs) and data collection. Training will specifically focus
on study exclusion criteria, particularly the identification
of clinical conditions, e.g. pneumothorax or vomiting,
where administration of CPAP could be harmful. Training
strategies will include online training modules, small
group teaching, demonstration, hands-on familiarisation
and scenario-based practice. Only once an ambulance ser-
vice clinician has received this training and has been
assessed to be competent will they be permitted to enrol
patients into the trial. Research paramedics will provide
ongoing support and training as necessary, including
training of new ambulance service clinicians starting at
ambulance hubs after recruitment to the study has begun.
Data collection
A recruitment form (case report form (CRF) A), con-
tained within each equipment box, will be completed
every time a patient is enrolled in the trial. This will rec-
ord study number, basic demographic details, eligibility
criteria, suspected prehospital diagnosis,, consent details
and limited clinical and treatment data not routinely re-
corded, including a patient and ambulance service
clinician completed VAS dyspnoea scale (1–10) recorded
on initial assessment and immediately before ED arrival.
Routinely collected baseline characteristics, EMS tim-
ings, details of treatments provided and vital signs (in-
cluding peripheral oxygen saturations) en route to
hospital will be extracted from the ambulance service
patient report forms/electronic patient records into
ACUTE case report form B (CRF B) by research para-
medics. At 30 days, research paramedics will also review
the hospital records to record details of subsequent pro-
gress, treatments provided (including time to receiving
hospital NIV, if provided), length of hospital stay, use of
critical care, any adverse events (AEs) and status at
30 days. Any related AEs or serious AEs will be recorded
on the study case report form (CRF B).
Baseline quality of life assessments will be performed
by research paramedics shortly after hospital admission,
following confirmation of patient consent for participa-
tion in the trial. Patients, or their representatives, will be
asked to estimate their current health status, using the
EQ-5D-5L. This data will be recorded in the study case
report form (CRF B). Quality of life and resource use
will also be assessed remotely by questionnaire at 30 days
following enrolment. Participants will be asked for their
preferred method for data collection, either telephone or
postal. Initial non-responders will be contacted again
after a further 2 weeks by telephone or post. Key ele-
ments of health care resource use to be recorded will in-
clude hospital services and GP or community services.
Participants will also be asked to report any AEs in the
30-day follow-up questionnaire. For patients’ declining
consent for follow-up, anonymised 30-day mortality will
be recorded. The assessments and follow-up for the
ACUTE trial are summarised in Table 2.
Data management
All data will be collected and retained in accordance
with the UK Data Protection Act 1998 and University of
Sheffield clinical trials and research unit (CTRU) stand-
ard operating procedures (SOPs). Trial data will be ex-
tracted from source documents and CRFs and entered
onto a secure data management system. Patient identifi-
able data (names, date of birth and contact details) will
only be collected and entered on the prospect database
when written informed consent has been confirmed. Val-
idation reports will be run regularly to check the study
data for completeness, accuracy and consistency. Dis-
crepancies will be generated, monitored and managed by
research paramedics to resolution.
Sample size and statistical analyses
Participant recruitment and retention will be presented
with a CONSORT flow diagram [18]. The following
feasibility outcomes will then be reported descriptively
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for the whole trial population, together with their 95%
confidence interval (calculated using the Wilson score
method) [19]:
1. Recruitment rate per 100,000 population per year
(target 8, i.e. 120 across the 1.5 million population
of the 4 WMAS hubs)
2. Proportion recruited in error and classified as
minor or major non-compliances (target 0 and ≤%)
3. Adherence to the allocation schedule (target ≥ 90%)
4. Adherence to treatment in the CPAP arm
(target ≥ 75%)
5. Retention at 30 days (target ≥ 90%)
6. Data completeness (target ≥ 90%)
Summary estimates of effectiveness outcomes will also
be reported, for the whole trial population and separ-
ately per treatment group, with 95% confidence intervals
using an as-randomised analysis:
1. Proportion surviving to 30 days
2. Proportion undergoing endotracheal intubation by
30 days
3. Proportion admitted to critical care at any point up
to 30 days
4. Mean and median length of hospital stay
5. Change in VAS dyspnoea score from initial
presentation versus immediately before ED arrival
6. Mean EQ-5D-5L
Table 2 Summary of data collection and trial documentation
What Where Who How When
Baseline Hospital
admission
30 days
Consent form
•Verbal consent Scene of incident Paramedics Verbal X
•Written informed consent Hospital Research
paramedic
Paper X
Case report form A
•Patient demographics Scene of incident/emergency
department
Paramedics Paper X
•Patient characteristics Telephone X
•Prehospital treatments
•Adverse events
X
X
Case report form B
•Patient demographics Hospital Research
paramedic
Paper X
•Baseline quality of life X
•Inpatient treatments X
•30-day mortality X
•Intubation X
•Critical care admission X
•Length of stay
•Adverse events
X X
Patient questionnaire
•Quality of life Home Patient Paper X
•Resource use Research
paramedic
Telephone X
•Adverse events X
Paramedic questionnaire
•Acceptability of CPAP Home/work Paramedics Electronic X
HRA safety report form
•Unexpected related serious adverse
events
CTRU Chief investigator Electronic X X X
SAE form
•Other serious adverse events CTRU Chief investigator Paper X X X
CTRU clinical trials and research unit, SAE serious adverse event, CPAP continuous positive airways pressure
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7. Key elements of health care resource use up to
30 days
The ACUTE feasibility study aims to recruit n = 120
over 12 months. A minimum sample size of 120 was
proposed by Teare et al. for pilot studies with dichotom-
ous outcomes, based on the precision to which binary
parameters are estimated for use in the sample size cal-
culation of the full trial [20]. Mortality under standard
care is estimated at 12%, and for the full trial, a 5% abso-
lute reduction is postulated (i.e. to 7%) in the interven-
tion arm. With n = 120, we will therefore be estimated to
within a standard error of 2.7% and used in the sample
size calculation for the eventual trial. Given the short
follow-up period, loss to follow-up of < 5% at 30 days is
envisaged. This sample size will allow estimation of
feasibility outcomes with a precision of < 5%.
A previous evidence synthesis study produced esti-
mates of the incidence of eligible cases ranging from 3.5
to 40.8 per 100,000 population per year [3, 9]. The low-
est estimates were based upon actual patients treated
with CPAP, in services with limited ability to deliver
treatment for all eligible patients and are likely to be un-
derestimates. The highest estimates were based upon
audit data for in-hospital NIV use among emergency ad-
missions and are likely to be overestimates. Assuming
that there are 20 eligible cases per 100,000 population
per year and 40% are recruited, 120 patients will be re-
cruited from the study’s source population of 1.5 million,
over 1 year.
Health economics
A previously published meta-analysis and decision ana-
lysis model evaluating the cost-effectiveness of prehospi-
tal CPAP for ARF will be updated [3, 9, 21]. The
decision analysis model simulates the management, out-
comes and costs of a hypothetical cohort of patients
transported to hospital by emergency ambulance with
ARF. Effectiveness is estimated in terms of short-term
mortality, using odds ratios from the meta-analysis, and
valued as quality-adjusted life years (QALYs) [22]. Costs
are estimated from a health service perspective and in-
clude all costs related to delivering prehospital CPAP
and subsequent treatment of acute respiratory failure.
The cost of providing prehospital CPAP is estimated by
dividing the total cost of establishing and running the
service across an ambulance service by the total number
of patients treated.
The ACUTE pilot trial offers an ideal opportunity to
estimate the incidence of patients eligible for prehospital
CPAP and to update the model with an estimate that is
representative and applicable to the NHS. A literature
search will also be conducted for new randomised con-
trolled trials comparing prehospital CPAP to standard
care; if any are found, the meta-analysis will be updated
along with effectiveness data from the ACUTE study.
The outputs of the model will be updated estimates of
the cost-effectiveness of prehospital CPAP, expressed as
the incremental cost per QALY gained by CPAP com-
pared to standard care and the probability of CPAP be-
ing cost-effective at £20,000/QALY and £30,000/QALY
thresholds for willingness to pay. Expected value of sam-
ple information (EVSI) and expected net benefit of sam-
pling (ENBS) for a range of future randomised trial
sample sizes will also be calculated. Extensive sensitivity
analyses will be performed to explore decision uncer-
tainty including examination of future scenarios where
CPAP technology changes in cost or efficacy.
Trial oversight, ethics and governance
The trial has been reviewed and approved by the NHS
Leeds East Research Ethics Committee. The University
of Sheffield is providing sponsorship and monitoring
oversight for the project, and the trial will be conducted
in line with the relevant sponsor SOPs. The Sheffield
CTRU is responsible for trial management, oversight of
data collection, statistical analysis and the health eco-
nomics analysis. A Trial Management Group (TMG)
comprising the applicants and relevant members of the
CTRU team will provide ongoing trial support, have re-
sponsibility for interpreting the data and writing and
reviewing the final report. An independent Trial Steering
Committee (TSC) and Data Monitoring and Ethics
Committee (DMEC) have been established to oversee
the safety, conduct and progress of the study.
Discussion
The ACUTE study will determine the feasibility, accept-
ability and cost-effectiveness of a definitive trial to evalu-
ate the clinical and cost-effectiveness of prehospital
CPAP, compared to standard oxygen therapy, for pa-
tients attended by ambulance service clinicians with
ARF. Recruitment of at least 120 participants to the pilot
trial over 12 months will demonstrate that a definitive
trial is feasible and cost-effective. It will also allow esti-
mation of adherence, attrition, data completeness and
event rates with sufficient precision to ensure validity of
the definitive trial protocol. A sample size of 1518 is
projected for the full trial (based on 5% absolute effect
size, 88% baseline 30-day survival, 90% power, two-sided
significance of 5%, 5% attrition at 30 days).
Important design issues during the development of the
ACUTE protocol were the choice of CPAP device,
method of randomisation/allocation concealment and
consent processes. There is a wide array of possible
methods for administering prehospital CPAP [16]. A
single-use disposable unit was chosen over a CPAP ma-
chine on the basis of cheaper cost, simplicity of use and
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portability. The O_two unit offers several advantages
over competing devices. It has low oxygen flow rates,
allowing prolonged use without depleting ambulance
oxygen stores. It may also be used with portable oxygen
cylinders, offering the possibility to commence treatment
in a patient’s home. As an open system, with access to
ambient air, the device allows unrestricted inspiratory
flows and is unaffected by respiratory rate. A potential
disadvantage is that the level of CPAP is varied by alter-
ing the incoming oxygen flow rate. Thus, the inspired
concentration of oxygen cannot be varied independently
from the degree of CPAP. The prehospital time interval,
and changes in patient physiology (peripheral oxygen
saturations, respiratory rate, and dyspnoea score), will be
recorded to evaluate any transport delays or prehospital
deterioration following introduction of a new EMS treat-
ment. The O_two CPAP device has also been used in
Australian and Canadian emergency medical services
with an excellent safety record. A range of healthcare
practitioners have successfully provided CPAP in these
settings (including entry-level technicians, paramedics
and critical care paramedics); however, it is possible that
effectiveness could vary according to clinician skill and
experience.
Cluster randomisation has been used extensively in
previous prehospital trials but is limited by a high risk of
post-randomisation selection and other biases [23]. Indi-
vidual randomisation is preferred to maximise internal
validity [24] but is challenged by the time-pressured and
confused prehospital environment. Central telephone
randomisation has not been found to be feasible, and se-
quentially numbered envelopes have well known limita-
tions. We therefore implemented randomisation using
identical trial equipment boxes, packaged according to
the randomisation schedule. Packaging was designed to
be identical in weight, feel and appearance across trial
arms. Research paramedics will closely monitor equip-
ment boxes during the trial to detect any attempts to
subvert the randomisation sequence.
Emergency trials will often need to recruit unwell, in-
capacitated patients. As the most severe ARF patients
are most likely to benefit from CPAP, it is not possible
to exclude such patients from the trial. In accordance
with the Declaration of Helsinki, UK MCA 2005 and
Good Clinical Practice guidelines, a hierarchical consent
process was designed [14, 25, 26]. Ambulance service
clinicians assess capacity as a core skill and will obtain
verbal consent for participation if patients can retain,
weigh, use and communicate information. In common
with other prehospital trials, patients without capacity
can be enrolled without consent. At the earliest oppor-
tunity after admission to hospital, formal written in-
formed consent will be confirmed with patients or their
consultees. These consent procedures were developed in
accordance with best practice and after consultation
with patient and public representatives, prior to review
and approval by an independent research ethics
committee.
Trial status
The current protocol is version 2 (16 February 2017).
The current protocol version is available from the study
website (www.sheffield.ac.uk/acute). The trial opened to
recruitment in August 2017. Recruitment is anticipated
to run until 31 July 2018 with trial completion by 31 De-
cember 2018. As of December 2017, 25% of the study
population was recruited.
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